Envista Holdings Corp
HealthcareNYSE:NVST · New York Stock Exchange
+$0.10 today
Vol 2.17M · Avg 2.97M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
1.5%
avg -0.7%
ROIC
1.2%
avg 0.1%
ROA
0.8%
avg 0.0%
Analysis
ROE is currently the strongest return metric at 1.5% versus its period average of -0.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Paul A. Keel | Chief Executive Officer & Director | $3.76M | — | 56 | $371,574.00 | 0.23% |
Eric D. Hammes | Senior Vice President & Chief Financial Officer | $1.35M | — | 51 | $110,798.00 | 0.07% |
Veronica Acurio | Senior Vice President & President of Orthodontics | $1.32M | — | 55 | $13,845.00 | <0.01% |
Mark E. Nance | Senior Vice President, General Counsel & Secretary | $1.15M | — | 57 | $81,252.00 | 0.05% |
Robert Befidi Jr. | Senior VP & President of Diagnostics | $1.09M | — | 51 | $50,932.00 | 0.03% |
Mischa Reis | Senior Vice President of Strategy & Corporate Development | $848,850.00 | — | 53 | $35,321.00 | 0.02% |
Jim Gustafson | Vice President of Investor Relations | $453,728.00 | — | — | — | — |
Andrew Chen | Chief Information Officer | — | — | — | $18,485.00 | 0.01% |
Suraj Satpathy | Chief Human Resources officer | — | — | — | — | — |
Faez Kaabi | Vice President, Chief Accounting Officer & Corporate Controller | — | — | 57 | $58,552.00 | 0.04% |
Stefan Nilsson | President of Nobel Biocare | — | — | 55 | $62,364.00 | 0.04% |
Paul Sumilas | Chief Compliance Officer | — | — | — | $371,574.00 | 0.23% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
2
$493,020.00
Net Sentiment
$493,020.00
Net selling
Most Active
Reis Mischa
2 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Feb 10, 2026 | Reis Mischa Direct | Sell | 5.6K | $30.00 | $169,020.00 | |
| Aug 25, 2025 | Reis Mischa Direct | Sell | 15.0K | $21.60 | $324,000.00 |
Analysis
Insiders reported 0 buys worth $0.00 and 2 sells worth $493,020.00 over the last 12 months. That adds up to net selling of $493,020.00. Reis Mischa was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -52.0% | +24.8% (9yr)2 analysts |
| Revenue | N/A | N/A | -11.8% | +5.7% (9yr)5 analysts |
| Net Income | N/A | N/A | -52.0% | +28.7% (9yr)5 analysts |
| EBIT | N/A | N/A | -51.7% | +26.3% (9yr)5 analysts |
Analysis
Recent growth has been strongest in Revenue at -11.8% over three years. Forward estimates point to Net Income at +28.7% (9yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.47B
Alignment Healthcare, Inc.
NASDAQ:ALHC
$4.08B
Concentra Group Holdings Parent, Inc.
NYSE:CON
$3.60B
ICU Medical, Inc.
NASDAQ:ICUI
$3.55B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.01B
Privia Health Group, Inc.
NASDAQ:PRVA
$2.95B
Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
$2.58B
GRAIL, Inc.
NASDAQ:GRAL
$2.57B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.40B
DENTSPLY SIRONA Inc.
NASDAQ:XRAY
$2.02B
Who manages NVST?
Envista Holdings Corp (NVST) lists 12 active executives. The top listed executive is Andrew Chen, Chief Information Officer.
Are NVST insiders buying or selling?
Recent insider activity shows net buying of $40.93M.
Explore More
Continue the stock analysis
Jump to another research area for this company.